NCT07248774 Effect of Bubble Positive Expiratory Pressure and Segmental Breathing Versus Incentive Spirometry in Pleural Effusion
| NCT ID | NCT07248774 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Pleural Effusion |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-10-28 |
| Primary Completion | 2026-01-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-10-28 with a primary completion date of 2026-01-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Conducted as a randomized clinical trial, this study will include 40 pediatric participants aged 5-16, recruited from Gulab Devi Chest Hospital and Children's Hospital, Lahore. Participants will be randomly divided into two groups: one receiving Bubble PEP with Segmental Breathing and the other using Incentive Spirometry, both combined with conventional chest physiotherapy and mobility. Outcome measures, including lung expansion (via X-ray), dyspnea (assessed using the Pediatric Dyspnea Scale), chest expansion (measured with a measuring tape), oxygen saturation (SpO₂), and respiratory rate, will be recorded pre- and post-intervention. The study hypothesises that the Bubble PEP and Segmental Breathing approach may offer a cost-effective and efficient alternative to Incentive Spirometry, particularly for patients who cannot afford mechanical devices. Statistical analysis will be performed using SPSS version 2023 to determine the intervention's effects.
Eligibility Criteria
Inclusion Criteria: * Age 5 to 16. * Suffering from Pleural effusion or hydrothorax. * Thoracic drainage system in situ for 24 hours. * Either gender will be included. * Patients without any other co-existing illness. Exclusion Criteria: * Any other pulmonary pathology that does not fit the diagnostic criteria of Pleural Effusion. * Participants with unbearable chest pain, chylothorax, hemothorax, pneumothorax, chest trauma or rib fracture. * Participants with other comorbidities leading to pleural effusion. * Patients who have chest musculoskeletal deformities.
Contact & Investigator
Tayyba Bari, MS-PT
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07248774 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 16 Years, studying Pleural Effusion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07248774 currently recruiting?
Yes, NCT07248774 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT07248774 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07248774 clinical trial?
NCT07248774 is sponsored by Riphah International University. The principal investigator is Tayyba Bari, MS-PT at Riphah International University. The trial plans to enroll 40 participants.